Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q2- Text added to 2019 Q3
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
angiogenic, appeal, axitinib, Bausch, burden, Canada, care, chemistry, cited, confirm, consent, consented, CRL, degeneration, delivery, digit, dispose, entry, Health, inhibitor, instance, Ireland, joint, large, maximum, microneedle, notice, ophthalmology, percent, promote, ready, refund, refunded, regain, REGENXBIO, reinspection, repaid, respond, resubmission, resubmit, resubmitted, retained, royalty, Rule, settlement, sublicensable, testing, tiered, twenty, vascular, venture, world, worldwide, written, XIPERETM
Valuein 2019 Q2 filing- Value in 2019 Q3 filing
Original filings
Filing view